In the BioHarmony Drug Report Database

"Preview" Icon

Dalbavancin

Dalvance, Xydalba (dalbavancin) is an unknown pharmaceutical. Dalbavancin was first approved as Dalvance on 2014-05-23. It is used to treat bacterial infections, infectious skin diseases, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial skin diseases and soft tissue infections. Dalvance’s patents are valid until 2023-12-25 (FDA).

 

Trade Name

 

Xydalba
 

Common Name

 

dalbavancin
 

ChEMBL ID

 

CHEMBL3301669
 

Indication

 

bacterial infections, bacterial skin diseases, infectious skin diseases, soft tissue infections, staphylococcal infections, streptococcal infections
 

Drug Class

 

Vancomycin-related compounds

Image (chem structure or protein)

Dalbavancin structure rendering